Working... Menu

An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02418455
Recruitment Status : Completed
First Posted : April 16, 2015
Last Update Posted : April 2, 2019
Information provided by (Responsible Party):
Ultragenyx Pharmaceutical Inc

Brief Summary:
UX003-CL203 is an open-label, multi-center, Phase 2 study to assess the safety and efficacy of UX003 in pediatric MPS 7 subjects.

Condition or disease Intervention/treatment Phase
Sly Syndrome MPS VII Mucopolysaccharidosis Mucopolysaccharidosis VII Drug: UX003 Phase 2

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Actual Study Start Date : July 21, 2015
Actual Primary Completion Date : March 26, 2019
Actual Study Completion Date : March 26, 2019

Arm Intervention/treatment
Experimental: 4 mg/kg of UX003
Initial treatment period 48 weeks. Continuation period up to 240 weeks.
Drug: UX003
Other Names:
  • recombinant human beta-glucoronidase
  • rhGUS
  • Mepsevii ™
  • vestronidase alfa-vjbk
  • vestronidase alfa

Primary Outcome Measures :
  1. Percent Change From Baseline in Urinary Glycosaminoglycans (uGAG) Excretion at Week 48 [ Time Frame: Baseline (Week 0), Week 48 ]
    Determined by the percent reduction of uGAG excretion after 48 weeks of treatment relative to the pre-treatment baseline.

  2. Safety and tolerability of UX003 (severity, frequency, and number of Adverse Events and Serious Adverse Events) [ Time Frame: Initial treatment period 48 weeks. Continuation period up to 240 weeks. ]

Secondary Outcome Measures :
  1. Change From Baseline in Growth Velocity at Week 48 [ Time Frame: Baseline (Week 0), Week 48 ]
    Determined by changes in growth velocity after 48 weeks of treatment relative to pre-treatment baseline and published normative data for age and gender.

  2. Change From Baseline in Hepatosplenomegaly at Week 48 [ Time Frame: Baseline (Week 0), Week 48 ]
    Determined by the volume of the liver and spleen after 48 weeks of treatment relative to pre-treatment baseline and normal values for age and gender.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Confirmed diagnosis of MPS 7 based on leukocyte or fibroblast glucuronidase enzyme assay, or genetic testing.
  2. Under 5 years of age at the time of informed consent.
  3. Written informed consent of Legally Authorized Representative after the nature of the study has been explained, and prior to any research-related procedures.

Exclusion Criteria:

  1. Undergone a successful bone marrow or stem cell transplant or has evidence of any degree of detectable chimaerism with donor cells.
  2. Any known hypersensitivity to rhGUS or its excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects.
  3. Use of any investigational product (drug or device or combination) other than UX003 within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments at any time during the study.
  4. Has a condition of such severity and acuity, in the opinion of the Investigator, which may not allow safe study participation. For patients with hydrops fetalis, the ongoing interventions to manage fluid balance can be continued; if the addition of enzyme replacement therapy (ERT) is considered a fluid-overload risk, the individual should be excluded.
  5. Has a concurrent disease or condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or affect safety. Since hydropic patients have a high rate of mortality, the risk of death prior to 1 year of age should not be considered sufficient to exclude the patient from the study for compliance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02418455

Layout table for location information
United States, District of Columbia
Children's National Health System
Washington, District of Columbia, United States, 20010
United States, New York
New York University Langone Medical Center
New York, New York, United States, 10038
United States, Utah
University of Utah Hospital
Salt Lake City, Utah, United States, 84132
Centro Hospitalar do Porto
Porto, Portugal, 4099-345
Hospital Universitario Virgen Del Rocio
Sevilla, Spain, 41013
Sponsors and Collaborators
Ultragenyx Pharmaceutical Inc
Layout table for investigator information
Study Director: Medical Director Ultragenyx Pharmaceutical Inc

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ultragenyx Pharmaceutical Inc Identifier: NCT02418455     History of Changes
Other Study ID Numbers: UX003-CL203
2015-000104-26 ( EudraCT Number )
First Posted: April 16, 2015    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: April 2019

Keywords provided by Ultragenyx Pharmaceutical Inc:
Sly Syndrome
Enzyme Replacement Therapy
Rare Disease
Mucopolysaccharidosis type 7
Lysosomal Storage Disease
Metabolic Disorder

Additional relevant MeSH terms:
Layout table for MeSH terms
Mucopolysaccharidosis VII
Pathologic Processes
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Connective Tissue Diseases
Metabolic Diseases